CN114306535A - Toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and preparation method thereof - Google Patents
Toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and preparation method thereof Download PDFInfo
- Publication number
- CN114306535A CN114306535A CN202111664107.2A CN202111664107A CN114306535A CN 114306535 A CN114306535 A CN 114306535A CN 202111664107 A CN202111664107 A CN 202111664107A CN 114306535 A CN114306535 A CN 114306535A
- Authority
- CN
- China
- Prior art keywords
- parts
- toxin
- dissolving
- virus
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 52
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 52
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 45
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 41
- 208000000419 Chronic Hepatitis B Diseases 0.000 title claims abstract description 37
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 35
- 230000000415 inactivating effect Effects 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000003053 toxin Substances 0.000 title claims abstract description 21
- 231100000765 toxin Toxicity 0.000 title claims abstract description 21
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 29
- 239000011669 selenium Substances 0.000 claims abstract description 29
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 26
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 25
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 25
- 229940082787 spirulina Drugs 0.000 claims abstract description 25
- 240000007087 Apium graveolens Species 0.000 claims abstract description 20
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims abstract description 20
- 235000010591 Appio Nutrition 0.000 claims abstract description 20
- 229920001661 Chitosan Polymers 0.000 claims abstract description 13
- 229920001202 Inulin Polymers 0.000 claims abstract description 13
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 13
- IKNAJTLCCWPIQD-UHFFFAOYSA-K cerium(3+);lanthanum(3+);neodymium(3+);oxygen(2-);phosphate Chemical compound [O-2].[La+3].[Ce+3].[Nd+3].[O-]P([O-])([O-])=O IKNAJTLCCWPIQD-UHFFFAOYSA-K 0.000 claims abstract description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 13
- 229940029339 inulin Drugs 0.000 claims abstract description 13
- 229910052590 monazite Inorganic materials 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 235000001270 Allium sibiricum Nutrition 0.000 claims abstract description 8
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 8
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 8
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 8
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 8
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930184510 Mallotus Natural products 0.000 claims abstract description 6
- 241001060384 Mallotus <angiosperm> Species 0.000 claims abstract description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 6
- 235000011477 liquorice Nutrition 0.000 claims abstract description 6
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 40
- 238000000855 fermentation Methods 0.000 claims description 36
- 230000004151 fermentation Effects 0.000 claims description 36
- 238000001914 filtration Methods 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 15
- 238000010025 steaming Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 230000003592 biomimetic effect Effects 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 10
- 239000004744 fabric Substances 0.000 claims description 5
- 238000010304 firing Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000002002 slurry Substances 0.000 claims description 5
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 240000007124 Brassica oleracea Species 0.000 claims description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 2
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 claims description 2
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 claims description 2
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 claims description 2
- 235000011305 Capsella bursa pastoris Nutrition 0.000 claims description 2
- 240000008867 Capsella bursa-pastoris Species 0.000 claims description 2
- 244000301850 Cupressus sempervirens Species 0.000 claims description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 2
- 244000178289 Verbascum thapsus Species 0.000 claims description 2
- 235000010599 Verbascum thapsus Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 6
- 230000002779 inactivation Effects 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000972672 Phellodendron Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000001320 lysogenic effect Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041519 Spider naevus Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof, and relates to the technical field of biological medicine. The toxin-dissolving bionic enzyme is prepared from the following raw materials: phellodendron bark, liquorice, celery, wormwood, mallotus root, chive, spirulina, monazite, calcium carbonate, inulin, chitosan and organic selenium. The toxin-dissolving bionic enzyme prepared by the invention can effectively inactivate chronic hepatitis B virus, the inactivation rate reaches more than 99.99 percent, and cells are not damaged. In addition, the preparation method provided by the invention is simple and easy to operate, and is suitable for industrial large-scale production.
Description
The technical field is as follows:
the invention relates to the technical field of biological medicines, in particular to a toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof.
Background art:
hepatitis B Virus (HBV) is a DNA Virus causing acute or chronic Hepatitis in human beings. Hepatitis b is a disease caused by the hepatitis b virus, is transmitted mainly through body fluids, and is a common blood-borne pathogen worldwide. Hepatitis b virus causes liver disease, and some patients may cause cirrhosis and liver cancer, or even death. Patients with hepatitis B often feel weak physical strength, easy fatigue, inappetence, nausea, aversion to oil, discomfort of the upper abdomen, liver and spleen swelling and pain of the liver area, and some patients can have discomfort and dull pain of the right upper abdomen and right monzonular part; jaundice of the eyes or skin occurs. Patients with severe hepatitis B or chronic hepatitis B are dark and dark in complexion; spider nevi are seen on the face, neck, chest and back of the hand. Chronic hepatitis b is a common condition, and an infected person may have no symptoms at all, but cirrhosis and even liver cancer can be caused, and hepatitis b virus can be continuously removed for years to decades because the body needs to remove the hepatitis b virus repeatedly in the chronic infection process of the hepatitis b virus. At present, common anti-hepatitis B virus medicines comprise interferon and nucleoside analogues, and the medicines can only inhibit hepatitis B virus functionally and are difficult to realize functional cure of the hepatitis B virus.
The virus is a non-cell life form, which is composed of a long nucleic acid chain and a protein shell, and has no own metabolic mechanism and no enzyme system. The virus leaves the host cell and becomes a chemical substance which has no life activity and can not independently propagate. Therefore, viruses and human cells are almost the same living environment, and no medical treatment means for site-specific inactivation of viruses without damaging self cells exists at present. In order to solve the existing technical problems, the development of a product which can inactivate the chronic hepatitis B virus and simultaneously protect the cells of the product from being damaged has important significance.
The invention content is as follows:
the invention aims to provide a toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof. The toxin-dissolving bionic enzyme prepared by the invention can effectively inactivate chronic hepatitis B virus without damaging cells.
The invention provides a toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus, which is prepared from the following raw materials in parts by weight: 500 parts of 200-200 parts of phellodendron bark, 600 parts of 300-600 parts of licorice root, 400 parts of 150-150 parts of celery, 400 parts of 200-400 parts of wormwood, 450 parts of root of divaricate velvetplant, 300 parts of chive, 80-150 parts of spirulina, 20-50 parts of monazite, 20-50 parts of calcium carbonate, 10-20 parts of inulin, 10-20 parts of chitosan and 15-30 parts of organic selenium.
Preferably, the weight ratio of celery to spirulina is 1-5:1, more preferably, the weight ratio of celery to spirulina is 3: 1.
Further preferably, the toxin-dissolving biomimetic enzyme is prepared from the following raw materials in parts by weight: 300 parts of golden cypress, 400 parts of liquorice, 300 parts of celery, 300 parts of wormwood, 350 parts of mallotus root, 200 parts of chive, 100 parts of spirulina, 40 parts of monazite, 40 parts of calcium carbonate, 16 parts of inulin, 14 parts of chitosan and 20 parts of organic selenium.
The organic selenium is one of selenium-rich yeast, selenium carrageenan, selenium-rich malt powder extract, selenium-rich shepherd's purse powder extract, selenium-rich Chinese cabbage powder extract and selenium-rich cabbage powder extract.
On the other hand, the invention provides a preparation method of the virus dissolving bionic enzyme for inactivating chronic hepatitis B virus, which comprises the following steps:
(1) taking cleaned cortex Phellodendri, Glycyrrhrizae radix, herba Apii Graveolentis, folium Artemisiae Argyi, radix Malloti Apeltae and herba Alii Fistulosi, pulverizing into slurry, filtering to remove residue, taking juice, adding Spirulina according to weight parts into the juice, steaming for 40-70min, filtering to obtain liquid, and naturally cooling;
(2) adding inulin into the liquid obtained in the step (1) according to the weight part, uniformly stirring, placing in a fermentation tank, standing at 25-36 ℃ for 24-36h, and filtering to obtain fermentation liquid 1;
(3) adding chitosan in parts by weight into the fermentation broth 1 obtained in the step (2), uniformly stirring, placing in a fermentation tank, standing at 25-36 ℃ for 24-36h, filtering to obtain a fermentation broth 2, distilling with a steaming furnace until no distillate exists, and obtaining a distilled fermentation broth;
(4) crushing monazite and calcium carbonate according to the weight parts, placing the powder in a 1800-plus-one 2200-DEG C high-temperature furnace, firing for 75-95min, cooling, placing the fired powder in a 800-plus-one 1200-mesh cloth bag, and distilling by using a steaming furnace to obtain a distillate;
(5) and (3) mixing organic selenium according to parts by weight with the distilled fermentation liquor obtained in the step (3) and the distillate obtained in the step (4), uniformly stirring to obtain a mixed liquor, adding n-hexane into the mixed liquor, keeping the n-hexane layer, and recovering n-hexane till the n-hexane layer is completely removed to obtain the toxin-dissolving bionic enzyme for inactivating the chronic hepatitis B virus.
The invention also provides the application of the toxin-dissolving bionic enzyme in inactivating chronic hepatitis B virus products. For example, the lyotropic biomimetic enzyme may be used alone or may be added to a mouth mask, alcohol, sterile water, charcoal bag, and the like.
Some physiological active substances generated by the toxin-dissolving bionic enzyme comprise amino acid, peptide, vitamin, polysaccharide, polyphenol, flavonoid, alcohol, ester, enzyme, mineral element, organic acid, various probiotics and the like, and have the functions of dissolving virus shell protein, deodorizing, purifying air, purifying water body, resisting bacteria and inhibiting bacteria. The probiotics of the human body has cell wall protection, the living cells have cell membrane protection, the virus has no cell wall and cell membrane, only has protein shell, the toxin-dissolving bionic enzyme can combine with protein, once the shell of the virus is disintegrated by the toxin-dissolving enzyme, the activity and the toxicity are lost, so the toxin-dissolving bionic enzyme only inactivates the virus, does not harm beneficial bacteria and cells of the human body, and makes up the defects of killing bacteria and viruses, killing fungi and cells by other antibiotics, medicaments, disinfectants and the like.
The invention has the beneficial effects that:
the invention provides a virus-dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof, the prepared virus-dissolving bionic enzyme can effectively inactivate the chronic hepatitis B virus, the inactivation rate reaches more than 99.99 percent, and cells are not damaged; the invention also discovers that the effect of inactivating the chronic hepatitis B virus can be obviously enhanced by adjusting the proportion of the celery to the spirulina. In addition, the preparation method provided by the invention is simple and easy to operate, and is suitable for industrial large-scale production.
Detailed Description
In order to make the technical means, the original characteristics, the achieved purposes and the effects of the invention easily understood, the invention is further explained with the following embodiments, but the following embodiments are only the preferred embodiments of the invention, and not all embodiments. Based on the embodiments in the implementation, other embodiments obtained by those skilled in the art without any creative efforts belong to the protection scope of the present invention.
The experimental methods in the following examples are conventional methods unless otherwise specified, and materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1
A toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof are disclosed:
a toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus is prepared from the following raw materials in parts by weight: 200 parts of phellodendron, 300 parts of liquorice, 150 parts of celery, 200 parts of wormwood, 220 parts of mallotus root, 100 parts of chive, 80 parts of spirulina, 20 parts of monazite, 20 parts of calcium carbonate, 10 parts of inulin, 10 parts of chitosan and 15 parts of organic selenium (selenium-enriched yeast).
The preparation method of the toxin-dissolving biomimetic enzyme comprises the following steps:
(1) taking cleaned cortex Phellodendri, Glycyrrhrizae radix, herba Apii Graveolentis, folium Artemisiae Argyi, radix Malloti Apeltae and herba Alii Fistulosi, pulverizing into slurry, filtering to remove residue, taking juice, adding Spirulina according to weight parts into the juice, steaming for 40min, filtering to obtain liquid, and naturally cooling;
(2) adding inulin into the liquid obtained in the step (1) according to the weight part, uniformly stirring, placing in a fermentation tank, standing at 25 ℃ for 24h, and filtering to obtain fermentation liquid 1;
(3) adding chitosan in parts by weight into the fermentation broth 1 obtained in the step (2), uniformly stirring, placing in a fermentation tank, standing at 25 ℃ for 24h, filtering to obtain a fermentation broth 2, distilling with a steaming furnace until no distillate exists, and obtaining a distilled fermentation broth;
(4) crushing monazite and calcium carbonate according to the weight parts, placing the powder in a high-temperature furnace at 1800 ℃, firing for 75min, cooling, placing the fired powder in a cloth bag with 800 meshes, and distilling by using a steaming furnace to obtain distillate;
(5) and (3) mixing organic selenium according to parts by weight with the distilled fermentation liquor obtained in the step (3) and the distillate obtained in the step (4), uniformly stirring to obtain a mixed liquor, adding n-hexane into the mixed liquor, keeping the n-hexane layer, and recovering n-hexane till the n-hexane layer is completely removed to obtain the toxin-dissolving bionic enzyme for inactivating the chronic hepatitis B virus.
Example 2
A toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof are disclosed:
a toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus is prepared from the following raw materials in parts by weight: the toxin-dissolving bionic enzyme is prepared from the following raw materials in parts by weight: 300 parts of phellodendron, 400 parts of liquorice, 300 parts of celery, 300 parts of wormwood, 350 parts of mallotus root, 200 parts of chive, 100 parts of spirulina, 40 parts of monazite, 40 parts of calcium carbonate, 16 parts of inulin, 14 parts of chitosan and 20 parts of organic selenium (selenocarrageenan). Namely, the weight ratio of the celery to the spirulina is 3: 1.
The preparation method of the toxin-dissolving biomimetic enzyme comprises the following steps:
(1) taking cleaned cortex Phellodendri, Glycyrrhrizae radix, herba Apii Graveolentis, folium Artemisiae Argyi, radix Malloti Apeltae and herba Alii Fistulosi, pulverizing into slurry, filtering to remove residue, taking juice, adding Spirulina according to weight parts into the juice, steaming for 60min, filtering to obtain liquid, and naturally cooling;
(2) adding inulin into the liquid obtained in the step (1) according to the weight part, uniformly stirring, placing in a fermentation tank, standing at 30 ℃ for 28h, and filtering to obtain fermentation liquid 1;
(3) adding chitosan in parts by weight into the fermentation broth 1 obtained in the step (2), uniformly stirring, placing in a fermentation tank, standing at 30 ℃ for 28h, filtering to obtain a fermentation broth 2, distilling with a steaming furnace until no distillate exists, and obtaining a distilled fermentation broth;
(4) crushing monazite and calcium carbonate according to the weight parts, placing the powder in a high-temperature furnace at 2000 ℃, firing for 85min, cooling, placing the fired powder in a 1000-mesh cloth bag, and distilling by using a steaming furnace to obtain distillate;
(5) and (3) mixing organic selenium according to parts by weight with the distilled fermentation liquor obtained in the step (3) and the distillate obtained in the step (4), uniformly stirring to obtain a mixed liquor, adding n-hexane into the mixed liquor, keeping the n-hexane layer, and recovering n-hexane till the n-hexane layer is completely removed to obtain the toxin-dissolving bionic enzyme for inactivating the chronic hepatitis B virus.
Example 3
A toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof are disclosed:
a toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus is prepared from the following raw materials in parts by weight: 500 parts of phellodendron, 600 parts of liquorice, 400 parts of celery, 400 parts of wormwood, 450 parts of mallotus root, 300 parts of chive, 150 parts of spirulina, 50 parts of monazite, 50 parts of calcium carbonate, 20 parts of inulin, 20 parts of chitosan and 30 parts of organic selenium (selenium-enriched malt powder extract).
The preparation method of the toxin-dissolving biomimetic enzyme comprises the following steps:
(1) taking cleaned cortex Phellodendri, Glycyrrhrizae radix, herba Apii Graveolentis, folium Artemisiae Argyi, radix Malloti Apeltae and herba Alii Fistulosi, pulverizing into slurry, filtering to remove residue, taking juice, adding Spirulina according to weight parts into the juice, steaming for 70min, filtering to obtain liquid, and naturally cooling;
(2) adding inulin into the liquid obtained in the step (1) according to the weight part, uniformly stirring, placing in a fermentation tank, standing at 36 ℃ for 36h, and filtering to obtain fermentation liquid 1;
(3) adding chitosan in parts by weight into the fermentation broth 1 obtained in the step (2), uniformly stirring, placing in a fermentation tank, standing at 36 ℃ for 36h, filtering to obtain a fermentation broth 2, distilling with a steaming furnace until no distillate exists, and obtaining a distilled fermentation broth;
(4) crushing monazite and calcium carbonate according to the weight parts, placing the powder in a high-temperature furnace at 2200 ℃, firing for 95min, cooling, placing the fired powder in a 1200-mesh cloth bag, and distilling by using a steaming furnace to obtain distillate;
(5) and (3) mixing organic selenium according to parts by weight with the distilled fermentation liquor obtained in the step (3) and the distillate obtained in the step (4), uniformly stirring to obtain a mixed liquor, adding n-hexane into the mixed liquor, keeping the n-hexane layer, and recovering n-hexane till the n-hexane layer is completely removed to obtain the toxin-dissolving bionic enzyme for inactivating the chronic hepatitis B virus.
Example 4
A toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof are disclosed:
the only difference from example 2 is that 150 parts of celery and 150 parts of spirulina, namely the weight ratio of the celery to the spirulina is 1: 1.
Example 5
A toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof are disclosed:
the only difference from example 2 is that 400 parts of celery and 80 parts of spirulina, namely the weight ratio of the celery to the spirulina is 5: 1.
Comparative example 1
A toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof are disclosed:
the only difference from example 2 is that no celery was added.
Comparative example 2
A toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof are disclosed:
the only difference from example 2 is that no spirulina was added.
Comparative example 3
A toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and a preparation method thereof are disclosed:
the only difference from example 2 is that the standing fermentation time for steps (2) and (3) in the preparation process was 20 h.
Test examples
The virus-inactivating test was carried out using the lysogenic biomimetic enzymes prepared in examples 1-5 and comparative examples 1-3.
The test method refers to disinfection technical Specification 2020 edition-2.1.1.10.7;
and (3) testing viruses: hepatitis b HBV virus, host cell: human liver cell line hepg2.2.15;
test drug concentrations (in terms of lysogenic biomimetic enzyme): 100 mu g/ml, and the solvent is normal saline; the action time is 2h respectively.
The test results are shown in table 1:
table 1: the invention has the inhibiting effect on hepatitis B HBV virus
And (4) test conclusion: the tests show that the virus-dissolving bionic enzyme for inactivating the chronic hepatitis B virus, which is obtained by the preparation method provided by the invention, can effectively inactivate the chronic hepatitis B virus, the inactivation rate reaches more than 99.99 percent, and cells are not damaged; comparing examples 2,4 and 5 with comparative examples 1 and 2, it is found that the effect of inactivating chronic hepatitis B virus can be obviously enhanced by adjusting the proportion of celery to spirulina, and the celery and the spirulina have synergistic effect.
It should be understood that the above examples are only for clearly illustrating the present invention and are not intended to limit the embodiments of the present invention. It is intended that the present invention be understood and implemented by those skilled in the art, and not limited thereto. Any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention should be included in the protection scope of the claims of the present invention.
Claims (6)
1. The toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus is characterized by being prepared from the following raw materials in parts by weight: 500 parts of 200-200 parts of phellodendron bark, 600 parts of 300-600 parts of licorice root, 400 parts of 150-150 parts of celery, 400 parts of 200-400 parts of wormwood, 450 parts of root of divaricate velvetplant, 300 parts of chive, 80-150 parts of spirulina, 20-50 parts of monazite, 20-50 parts of calcium carbonate, 10-20 parts of inulin, 10-20 parts of chitosan and 15-30 parts of organic selenium.
2. The lyso-biomimetic enzyme according to claim 1, wherein the weight ratio of celery to spirulina is 1-5: 1.
3. The toxin dissolving biomimetic enzyme according to claim 1, wherein the toxin dissolving biomimetic enzyme is prepared from the following raw materials in parts by weight: 300 parts of golden cypress, 400 parts of liquorice, 300 parts of celery, 300 parts of wormwood, 350 parts of mallotus root, 200 parts of chive, 100 parts of spirulina, 40 parts of monazite, 40 parts of calcium carbonate, 16 parts of inulin, 14 parts of chitosan and 20 parts of organic selenium.
4. The toxin dissolving biomimetic enzyme according to claim 3, wherein the organic selenium is one of selenium-rich yeast, selenium carrageenan, selenium-rich malt powder extract, selenium-rich shepherd's purse powder extract, selenium-rich Chinese cabbage powder extract, and selenium-rich cabbage powder extract.
5. The method for preparing the lyso-biomimetic enzyme according to claim 1, wherein the preparation method comprises the following steps:
(1) taking cleaned cortex Phellodendri, Glycyrrhrizae radix, herba Apii Graveolentis, folium Artemisiae Argyi, radix Malloti Apeltae and herba Alii Fistulosi, pulverizing into slurry, filtering to remove residue, taking juice, adding Spirulina according to weight parts into the juice, steaming for 40-70min, filtering to obtain liquid, and naturally cooling;
(2) adding inulin into the liquid obtained in the step (1) according to the weight part, uniformly stirring, placing in a fermentation tank, standing at 25-36 ℃ for 24-36h, and filtering to obtain fermentation liquid 1;
(3) adding chitosan in parts by weight into the fermentation broth 1 obtained in the step (2), uniformly stirring, placing in a fermentation tank, standing at 25-36 ℃ for 24-36h, filtering to obtain a fermentation broth 2, distilling with a steaming furnace until no distillate exists, and obtaining a distilled fermentation broth;
(4) crushing monazite and calcium carbonate according to the weight parts, placing the powder in a 1800-plus-one 2200-DEG C high-temperature furnace, firing for 75-95min, cooling, placing the fired powder in a 800-plus-one 1200-mesh cloth bag, and distilling by using a steaming furnace to obtain a distillate;
(5) and (3) mixing organic selenium according to parts by weight with the distilled fermentation liquor obtained in the step (3) and the distillate obtained in the step (4), uniformly stirring to obtain a mixed liquor, adding n-hexane into the mixed liquor, keeping the n-hexane layer, and recovering n-hexane till the n-hexane layer is completely removed to obtain the toxin-dissolving bionic enzyme for inactivating the chronic hepatitis B virus.
6. The toxin-solubilizing biomimetic enzyme according to any one of claims 1 to 4, wherein the toxin-solubilizing biomimetic enzyme is used for inactivating chronic hepatitis B virus products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111664107.2A CN114306535A (en) | 2021-12-31 | 2021-12-31 | Toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111664107.2A CN114306535A (en) | 2021-12-31 | 2021-12-31 | Toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114306535A true CN114306535A (en) | 2022-04-12 |
Family
ID=81021389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111664107.2A Pending CN114306535A (en) | 2021-12-31 | 2021-12-31 | Toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114306535A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584702A (en) * | 2009-06-19 | 2009-11-25 | 广西中医学院 | Method of preparing extract of Mallotus apelta and uses for fighting hepatitis B virus |
| CN102018751A (en) * | 2010-05-21 | 2011-04-20 | 中国人民解放军第三军医大学第一附属医院 | Anti-hepatitis natural medicine compound preparation, preparation method and application thereof |
| CN113069502A (en) * | 2021-03-07 | 2021-07-06 | 常德集智生物科技有限公司 | Toxin-dissolving bionic enzyme and preparation method thereof |
-
2021
- 2021-12-31 CN CN202111664107.2A patent/CN114306535A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584702A (en) * | 2009-06-19 | 2009-11-25 | 广西中医学院 | Method of preparing extract of Mallotus apelta and uses for fighting hepatitis B virus |
| CN102018751A (en) * | 2010-05-21 | 2011-04-20 | 中国人民解放军第三军医大学第一附属医院 | Anti-hepatitis natural medicine compound preparation, preparation method and application thereof |
| CN113069502A (en) * | 2021-03-07 | 2021-07-06 | 常德集智生物科技有限公司 | Toxin-dissolving bionic enzyme and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 安煜致等: "《病毒性肝炎防治的若干问题》", 31 August 2014, 辽宁科学技术出版社 * |
| 林丽文等: "芹菜素药理作用的研究进展", 《中国热带医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008528B (en) | Compound sea cucumber preparation and preparation method thereof | |
| Reynolds et al. | Viral inhibitors derived from macroalgae, microalgae, and cyanobacteria: A review of antiviral potential throughout pathogenesis | |
| CN101624570A (en) | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product | |
| CN106727738A (en) | A kind of Phellinus glossy ganoderma powder and preparation method thereof | |
| CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
| CN102743739A (en) | Preparation method for blattodea polypeptide substance, and medical use of blattodea polypeptide substance in anti-herpesvirus | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN105687036A (en) | Rhizoma bletillae skin care product and method for preparing same | |
| CN101647813A (en) | Bionic enzymatic hydrolysate for animal medicaments and application thereof | |
| CN114306535A (en) | Toxin dissolving bionic enzyme for inactivating chronic hepatitis B virus and preparation method thereof | |
| CN106389483A (en) | Medical fungi formula for preventing and treating diabetes and preparation method of medical fungi formula | |
| CN106389477B (en) | A kind of preparation method and application of the full cellular plant oil extract of Gordonia terrae | |
| CN106668077A (en) | Marine bioactive composition and pharmaceutical preparation | |
| CN105434895A (en) | Gastrodia elata rhodiola rosea cream and preparation method thereof | |
| CN106511401A (en) | Preparation method and application of cordyceps taii mycelia polysaccharides | |
| CN106606603A (en) | Dark tea extract, and applications of food-drug composition taking dark tea extract as main ingredient in radiation prevention | |
| CN110051759A (en) | A kind of Chinese medicinal composition preparation and preparation method thereof for treating liver cancer | |
| CN1476836A (en) | Anti-SARS action of zizhuisongguo chrysanthemum extract and its medicine composition | |
| CN110013497A (en) | A kind of Chinese medicinal soft capsule preparation process that immunity can be improved | |
| CN115501294B (en) | Preparation method and application of saccharomyces boulardii fermentation dioscorea opposita alcohol extract | |
| CN107802681B (en) | Composition for improving clinical symptom sign of HIV infected person | |
| CN106421154A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation containing Chinese eaglewood wood and having cell repairing, anti-aging and anti-canter functions as well as preparation method of traditional Chinese medicine composition | |
| CN1116069C (en) | Health care oral liquid for old people and preparation process thereof | |
| CN1824310A (en) | Preparation method of medicine for treating pelada | |
| CN107019740A (en) | It is a kind of to be used to prevent and treat Chinese medicine composition of virus B hepatitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220412 |
|
| RJ01 | Rejection of invention patent application after publication |